Patients who are suffering from a wide variety of pathological illnesses and neurodegenerative disorders, including cerebral ischemia or stroke, traumatic brain injury (TBI), and Alzheimer's disease, are included in this group and have been found to possess elevated levels of S100B in their cerebrospinal fluid and peripheral blood. Here, S100B is linked to early-onset autosomal dominant Alzheimer disease.